Efgivanermin Alfa Biosimilar – Anti-TNFRSF18 fusion protein – Research Grade

Introduction

Efgivanermin Alfa Biosimilar, also known as Anti-TNFRSF18 fusion protein, is a novel therapeutic antibody that has shown promising results in treating various autoimmune and inflammatory diseases. This biosimilar is a recombinant fusion protein that is designed to target the TNFRSF18 receptor, which plays a crucial role in regulating immune responses. In this article, we will discuss the structure, activity, and potential applications of Efgivanermin Alfa Biosimilar in detail.

Structure of Efgivanermin Alfa Biosimilar

Efgivanermin Alfa Biosimilar is a fusion protein that is composed of two different components – the extracellular domain of the TNFRSF18 receptor and the Fc fragment of human IgG1. The extracellular domain of the TNFRSF18 receptor is responsible for binding to its ligand, TNFSF18, while the Fc fragment of IgG1 provides stability and enhances the half-life of the protein. The two components are linked together by a flexible linker, which allows for proper folding and function of the fusion protein.

The recombinant fusion protein is produced through a mammalian cell expression system, which ensures the correct folding and post-translational modifications of the protein. The final product is a homodimer, with each monomer consisting of 218 amino acids. The molecular weight of the fusion protein is approximately 50 kDa.

Activity of Efgivanermin Alfa Biosimilar

Efgivanermin Alfa Biosimilar is a potent antagonist of the TNFRSF18 receptor, which is also known as glucocorticoid-induced TNFR-related protein (GITR). This receptor is expressed on various immune cells, including T cells, B cells, and dendritic cells, and is involved in regulating immune responses. The binding of the fusion protein to the TNFRSF18 receptor prevents the interaction between the receptor and its ligand, TNFSF18, thereby inhibiting downstream signaling pathways.

One of the key functions of the TNFRSF18 receptor is to promote the survival and proliferation of regulatory T cells (Tregs), which play a crucial role in maintaining immune homeostasis. The inhibition of the receptor by Efgivanermin Alfa Biosimilar leads to a decrease in the number and function of Tregs, resulting in the activation of effector T cells and the production of pro-inflammatory cytokines. This mechanism of action makes Efgivanermin Alfa Biosimilar a potential therapeutic option for autoimmune and inflammatory diseases.

Potential Applications of Efgivanermin Alfa Biosimilar

Efgivanermin Alfa Biosimilar has shown promising results in preclinical studies for various autoimmune and inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. The fusion protein has been shown to reduce disease severity and improve clinical symptoms in animal models of these diseases.

In addition, Efgivanermin Alfa Biosimilar has also demonstrated potential in cancer immunotherapy. The TNFRSF18 receptor is highly expressed on tumor-infiltrating lymphocytes and has been associated with poor prognosis in several types of cancer. By targeting this receptor, Efgivanermin Alfa Biosimilar can enhance anti-tumor immune responses and potentially improve the efficacy of cancer treatments.

Conclusion

Efgivanermin Alfa Biosimilar, also known as Anti-TNFRSF18 fusion protein, is a novel therapeutic antibody that targets the TNFRSF18 receptor. The fusion protein is composed of the extracellular domain of the receptor and the Fc fragment of human IgG1, and has shown promising results in preclinical studies for various autoimmune and inflammatory diseases. With its potent activity and potential applications in cancer immunotherapy, Efgivanermin Alfa Biosimilar holds great promise as a therapeutic option for a range of diseases.